IL13RA2 and familial pancreatic carcinoma: Interestingly, when cells were treated with histone deacetylase (HDAC) inhibitors, not only histone acetylation but also IL-13Rα2 expression was dramatically enhanced in IL-13-receptor negative pancreatic cancer cells.